Why wait? FDA gives early OK to Merck’s Keytruda for frontline lung cancer
That didn’t take long.
Two weeks after Merck $MRK made a triumphant victory march against Bristol-Myers Squibb on the frontline non-small cell lung cancer front …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
